Urocortin - RELIEF THERAPEUTICS Holding
Latest Information Update: 20 Sep 2023
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Anti-ischaemics; Hormones; Peptides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 20 Sep 2023 Discontinued - Preclinical for Hepatitis B in Switzerland (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Hepatitis-B in Switzerland
- 21 Sep 2016 Urocortin - RELIEF THERAPEUTICS Holding is available for licensing as of 21 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/